This product is a luciferase encoding oncolytic herpes simplex virus, which is based on HSV-1 with ICP0 deleted. The deletion of ICP0 were attenuated for viral growth, and impaired for viral reactivation when equivalent latent infections were established in vivo. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.
Specifications
Family
Herpesviridae
Species
Herpes simplex virus
Serotype
Herpes simplex virus 1
Backbone
HSV-1 (ΔΔICP0)
Backbone Background
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
Gene Modification
ΔΔICP0
Promoter
IE4/5
Transgene
luciferase
Type of Transgene
Reporter gene
Related Target/Protein
Luciferase
Capsid Modification
None
Titer
>1*10^8 PFU
Related Diseases
Osteosarcoma
Transgene
Alternative Names
luciferase, Fluc
Information
Introduction
Luciferase is a generic term for the class of oxidative enzymes that produce bioluminescence, and is usually distinguished from a photoprotein. Luciferases are widely used in biotechnology, for microscopy and as reporter genes, for many of the same applications as fluorescent proteins. However, unlike fluorescent proteins, luciferases do not require an external light source, but do require addition of luciferin, the consumable substrate.
Customer Reviews and Q&As
There are currently no customer reviews or questions for luciferase-encoding Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), IE4/5-luciferase (RepOV-0083XY). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.